Your browser doesn't support javascript.
IL-25 blockade augments antiviral immunity during respiratory virus infection.
Williams, Teresa C; Loo, Su-Ling; Nichol, Kristy S; Reid, Andrew T; Veerati, Punnam C; Esneau, Camille; Wark, Peter A B; Grainge, Christopher L; Knight, Darryl A; Vincent, Thomas; Jackson, Crystal L; Alton, Kirby; Shimkets, Richard A; Girkin, Jason L; Bartlett, Nathan W.
  • Williams TC; The University of Newcastle and Hunter Medical Research Institute, Newcastle, NSW, Australia.
  • Loo SL; The University of Newcastle and Hunter Medical Research Institute, Newcastle, NSW, Australia.
  • Nichol KS; The University of Newcastle and Hunter Medical Research Institute, Newcastle, NSW, Australia.
  • Reid AT; The University of Newcastle and Hunter Medical Research Institute, Newcastle, NSW, Australia.
  • Veerati PC; The University of Newcastle and Hunter Medical Research Institute, Newcastle, NSW, Australia.
  • Esneau C; The University of Newcastle and Hunter Medical Research Institute, Newcastle, NSW, Australia.
  • Wark PAB; The University of Newcastle and Hunter Medical Research Institute, Newcastle, NSW, Australia.
  • Grainge CL; Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, NSW, Australia.
  • Knight DA; The University of Newcastle and Hunter Medical Research Institute, Newcastle, NSW, Australia.
  • Vincent T; Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, NSW, Australia.
  • Jackson CL; The University of Newcastle and Hunter Medical Research Institute, Newcastle, NSW, Australia.
  • Alton K; UBC Providence Health Care Research Institute, Vancouver, BC, Canada.
  • Shimkets RA; Department of Anaesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada.
  • Girkin JL; Abeome Corporation/Lanier Biotherapeutics, Athens, GA, USA.
  • Bartlett NW; Abeome Corporation/Lanier Biotherapeutics, Athens, GA, USA.
Commun Biol ; 5(1): 415, 2022 05 04.
Article in English | MEDLINE | ID: covidwho-1890280
ABSTRACT
IL-25 is implicated in the pathogenesis of viral asthma exacerbations. However, the effect of IL-25 on antiviral immunity has yet to be elucidated. We observed abundant expression and colocalization of IL-25 and IL-25 receptor at the apical surface of uninfected airway epithelial cells and rhinovirus infection increased IL-25 expression. Analysis of immune transcriptome of rhinovirus-infected differentiated asthmatic bronchial epithelial cells (BECs) treated with an anti-IL-25 monoclonal antibody (LNR125) revealed a re-calibrated response defined by increased type I/III IFN and reduced expression of type-2 immune genes CCL26, IL1RL1 and IL-25 receptor. LNR125 treatment also increased type I/III IFN expression by coronavirus infected BECs. Exogenous IL-25 treatment increased viral load with suppressed innate immunity. In vivo LNR125 treatment reduced IL-25/type 2 cytokine expression and increased IFN-ß expression and reduced lung viral load. We define a new immune-regulatory role for IL-25 that directly inhibits virus induced airway epithelial cell innate anti-viral immunity.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Asthma / Virus Diseases / Interleukin-17 Limits: Humans Language: English Journal: Commun Biol Year: 2022 Document Type: Article Affiliation country: S42003-022-03367-z

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Asthma / Virus Diseases / Interleukin-17 Limits: Humans Language: English Journal: Commun Biol Year: 2022 Document Type: Article Affiliation country: S42003-022-03367-z